{"filings":[{"id":1555677,"accession_number":"0001438533-26-000054","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2026-07-09T21:10:23+00:00","items":["5.02"],"status":"ready","headline":"Travere Therapeutics CAO Sandra Calvin to retire; John Torell to succeed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sandra Calvin to retire as CAO/PAO after filing 10-K expected in February 2027.","John Torell, current VP Controller, to be appointed CAO/PAO before retirement date.","Torell joined Travere in 2021; previously VP Controller at Pacific Life and audit manager at Deloitte.","Torell holds CFA and CPA designations; transition plan aims for orderly handover."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1084919,"accession_number":"0001438533-26-000048","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2026-06-16T20:34:58+00:00","items":["5.02"],"status":"ready","headline":"Travere CRO William Rote to retire Feb 2027; CMO Inrig promoted to EVP, Head of R&D","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Rote, Ph.D., Chief Research Officer, to retire effective Feb 17, 2027, after 10 years.","Jula Inrig, M.D., current Chief Medical Officer, will assume Rote's responsibilities.","Effective July 1, 2026, Dr. Inrig becomes EVP, Head of R&D and Chief Medical Officer.","Travere expects to enter into a consulting arrangement with Dr. Rote post-retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787479,"accession_number":"0001193125-26-252474","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2026-06-02T11:05:07+00:00","items":["1.01","9.01"],"status":"ready","headline":"Travere licenses Everest's BTK inhibitor with $112.5M upfront, up to $1.03B milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive license for civorebrutinib (BTK inhibitor) outside China and select East/Southeast Asia countries.","Upfront payment of $112.5M; potential milestones up to ~$1.03B across up to five indications.","Tiered royalties from high single-digit to double-digit percentages on net sales in Territory.","Travere responsible for development and commercialization in Territory; global trial costs shared with Everest.","Deal effective upon HSR clearance; Travere can terminate and get upfront refund if tech transfer fails."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":581882,"accession_number":"0001438533-26-000046","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2026-05-21T20:07:19+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Travere shareholders approve 3M share increase under 2018 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2018 Plan, increasing authorized shares by 3,000,000 shares.","Ten directors elected to serve until 2027 annual meeting; all received majority votes.","Advisory say-on-pay resolution passed with 73.7M votes for (97.3% of votes cast).","Shareholders ratified Ernst & Young as independent auditor for fiscal year 2026.","Annual meeting held May 19, 2026; 81.1M shares (88% of outstanding) were represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":15244,"accession_number":"0001193125-26-217100","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2026-05-11T21:10:04+00:00","items":["1.01","8.01","2.03","3.02","9.01"],"status":"ready","headline":"Travere closes $525M 0.50% convertible note offering; uses proceeds to repurchase $221.4M of 2029 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed offering of $525M aggregate principal of 0.50% Convertible Senior Notes due 2032; net proceeds est. $508.5M.","Initial conversion price ~$64.90/share (15.4078 shares per $1,000 principal); notes mature May 15, 2032.","To repurchase $221.4M of outstanding 2.25% 2029 notes for approx. $350.9M, including accrued interest.","Remaining net proceeds for general corporate purposes, including commercialization and R&D.","Underwriters' over-allotment option fully exercised; offering upsized from $400M to $475M then to $525M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92887,"accession_number":"0001438533-26-000041","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere Q1 net product sales up 64% to $124.5M; FILSPARI approved for FSGS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FILSPARI net sales $105.2M (+88% YoY); 993 new PSFs in IgAN during Q1.","FDA approved FILSPARI for FSGS on April 13; first patients treated within a week.","Net loss $37.1M ($0.40/sh) vs $41.2M ($0.47/sh); non-GAAP net income $4.1M ($0.05/sh).","Phase 3 HARMONY of pegtibatinase restarted; first new patient dosed; topline data due 2H 2027.","Cash & equivalents $264.7M as of March 31; $25M milestone from Mirum received in April."],"consensus_eps_estimate":-0.2709,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":127199000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92886,"accession_number":"0001438533-26-000032","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves Travere's FILSPARI for FSGS without nephrotic syndrome, expanding label beyond IgAN","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved FILSPARI (sparsentan) for FSGS without nephrotic syndrome in patients aged 8+, second indication.","Addressable U.S. population estimated >30,000 individuals with FSGS without nephrotic syndrome.","Phase 3 DUPLEX: 48% proteinuria reduction in non-nephrotic patients vs 27% irbesartan (p=0.0075).","eGFR benefit: treatment difference 1.1 mL/min/1.73m2 at Week 108 favoring FILSPARI.","Safety profile comparable to irbesartan, consistent with prior programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104082,"accession_number":"0001438533-26-000013","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere reports Q4 net income of $2.7M; FILSPARI sales up 108% YoY to $103.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FILSPARI U.S. net product sales $103.3M in Q4 2025 (+108% YoY); full year $322M (+144%).","Q4 GAAP net income $2.7M ($0.03/share) vs net loss $60.3M in Q4 2024; non-GAAP net income $33.3M.","PDUFA target for FILSPARI in FSGS is April 13, 2026; commercial launch preparations ongoing.","Cash & securities $322.8M at Dec 31, 2025; expects $25M milestone from Mirum in H1 2026.","Phase 3 HARMONY study of pegtibatinase in HCU resumed enrollment; primary endpoint tHcy change."],"consensus_eps_estimate":-0.1204,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":490728000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104081,"accession_number":"0001438533-26-000005","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA extends FILSPARI FSGS sNDA PDUFA to April 13, 2026; cites Major Amendment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA extended PDUFA target action date to April 13, 2026, after determining supplemental NDA responses constitute a Major Amendment.","No safety or manufacturing concerns raised; FDA requested additional characterization of FILSPARI's clinical benefit in FSGS.","If approved, FILSPARI would be the first FDA-approved pharmacologic therapy for focal segmental glomerulosclerosis (FSGS).","Phase 3 DUPLEX study missed primary eGFR slope endpoint but showed proteinuria reduction and lower end-stage kidney disease rate vs irbesartan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104080,"accession_number":"0001438533-26-000003","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere reports record Q4 FILSPARI sales of $103M; FSGS PDUFA decision due Jan 13","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 2025 total U.S. net product sales ~$127M; FILSPARI sales ~$103M (+108% YoY).","FY2025 total U.S. net product sales ~$410M; FILSPARI full-year sales ~$322M.","Cash, equivalents and marketable securities ~$323M at year-end 2025.","FSGS sNDA PDUFA target date Jan 13, 2026; responses to FDA's info requests submitted and under review.","Pegtibatinase Phase 3 HARMONY study to restart in Q1 2026 after manufacturing optimization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120360,"accession_number":"0001438533-25-000055","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere reports Q3 net income of $25.7M; FILSPARI sales up 155% YoY to $90.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. FILSPARI net product sales $90.9M (+155% YoY); 731 new patient start forms in Q3.","Total revenue $164.9M incl. $40M milestone from CSL Vifor; net income $25.7M ($0.29 basic EPS) vs net loss of $54.8M in Q3 2024.","Remaining $68.9M of 2025 convertible notes retired; cash & equivalents $254.5M as of Sep 30 (excl. October milestone).","FDA sNDA for FILSPARI in FSGS under review; PDUFA target Jan 13, 2026; no advisory committee needed.","REMS modified removing embryo-fetal toxicity monitoring; KDIGO guidelines recommend FILSPARI as first-line therapy in IgAN."],"consensus_eps_estimate":-0.212,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":361039000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136932,"accession_number":"0001438533-25-000049","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA says no advisory committee needed for FILSPARI sNDA in FSGS; PDUFA Jan 13, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA informed Travere that an advisory committee is no longer needed for the FILSPARI (sparsentan) sNDA for FSGS.","The sNDA remains under review with a PDUFA target action date of January 13, 2026.","If approved, FILSPARI would be the first medication indicated for FSGS, a rare kidney disorder.","sNDA is supported by Phase 3 DUPLEX and Phase 2 DUET studies showing superior proteinuria reduction vs. irbesartan.","FILSPARI is already fully approved for IgA nephropathy in the US and EU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136931,"accession_number":"0001438533-25-000045","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere Q2 2025: FILSPARI sales $71.9M (+165% YoY); net loss narrows to $12.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. FILSPARI net product sales $71.9M, up 165% YoY; 745 new patient start forms received in Q2.","Total revenue $114.4M including $17.5M milestone from CSL Vifor; net product sales total $94.8M.","Net loss $12.8M ($0.14/share) vs $70.4M loss ($0.91/share) in Q2 2024; non-GAAP net income $11.9M.","Cash $319.5M; sNDA for FSGS accepted with PDUFA Jan 13, 2026; IgAN REMS modification PDUFA Aug 28, 2025.","R&D expense $49.4M (-9% YoY); SG&A expense $76.2M (+18% YoY)."],"consensus_eps_estimate":-0.3037,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":196180000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154186,"accession_number":"0001438533-25-000034","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Travere stockholders approve 4M-share increase in 2018 equity plan at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2018 Equity Incentive Plan, increasing authorized shares by 4,000,000 (71,802,001 votes for).","Ten directors elected to serve until 2026 annual meeting; all received majority votes with broker non-votes of ~4.4M.","Advisory vote on named executive officer compensation passed with 71,929,269 votes for.","Ratification of Ernst & Young as independent auditor for FY2025 approved (79,001,421 votes for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154185,"accession_number":"0001438533-25-000032","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA accepts Travere's sNDA for FILSPARI in FSGS; PDUFA Jan 13, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted sNDA for traditional approval of FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS).","PDUFA target action date is January 13, 2026; FDA plans an advisory committee meeting.","If approved, FILSPARI would be first FDA-approved drug for FSGS, affecting over 40,000 U.S. patients.","sNDA supported by Phase 3 DUPLEX (met interim proteinuria endpoint, missed primary eGFR slope) and Phase 2 DUET studies.","No approved pharmacologic treatment currently exists for FSGS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154184,"accession_number":"0001438533-25-000025","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere Q1 net product sales $75.9M; FILSPARI sales $55.9M, net loss narrows to $0.47/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $75.9M (1Q25) vs $40.0M (1Q24), driven by FILSPARI launch.","FILSPARI U.S. net sales $55.9M; 703 new patient start forms in quarter.","Net loss $41.2M ($0.47/share) vs $136.1M ($1.76/share) YoY; adj. net loss $16.9M.","Cash & securities $322.2M; sNDA submitted for full approval of FILSPARI in FSGS.","EU and UK converted FILSPARI to full approval in IgAN; $17.5M milestone from CSL Vifor expected Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":81732000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154182,"accession_number":"0001438533-25-000030","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K/A","filed_at":"2025-05-01T23:59:59+00:00","items":["2.01","2.02","9.01"],"status":"ready","headline":"Travere Q1 2025 net product sales $75.9M, FILSPARI U.S. sales up 182% YoY; net loss narrows to $41.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FILSPARI U.S. net product sales $55.9M in Q1 2025, up 182% YoY; 703 new patient start forms received.","Net loss of $41.2M ($0.47/share) vs $136.1M ($1.76) in Q1 2024; non-GAAP net loss $16.9M ($0.19).","sNDA for full approval of FILSPARI in FSGS submitted March 2025; FDA acceptance decision expected May 2025.","European Commission converted FILSPARI to standard MA for IgAN; expects $17.5M milestone from CSL Vifor in Q2 2025.","Cash, cash equivalents, and marketable securities $322.2M as of March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":81732000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154183,"accession_number":"0001438533-25-000020","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Travere's FILSPARI gets standard EU marketing authorization; receives $17.5M milestone","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["European Commission converts conditional approval to standard MA for FILSPARI (sparsentan) for primary IgAN in all EU member states, plus Iceland, Liechtenstein, Norway.","UK MHRA also converted to standard approval on April 15, 2025.","Company receives $17.5M milestone payment from CSL Vifor; eligible for additional market access and sales-based milestones.","Approval based on Phase 3 PROTECT Study showing significant slowing of kidney function decline vs. irbesartan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172781,"accession_number":"0001438533-25-000012","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Travere submits sNDA to FDA seeking priority review for FILSPARI in FSGS","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted sNDA on March 17, 2025 seeking priority review for traditional approval of FILSPARI (sparsentan) for FSGS.","Supported by Phase 3 DUPLEX study (interim FPRE endpoint met; primary eGFR slope missed) and Phase 2 DUET study (met primary endpoint).","FDA has 60 days to decide on acceptance; company expects notice in Q2 2025.","If approved, FILSPARI would be first FDA-approved therapy for FSGS, affecting >40,000 US patients.","No currently approved pharmacologic therapies for FSGS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172780,"accession_number":"0001438533-25-000008","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere Q4 FILSPARI sales $49.6M; plans FSGS sNDA by end Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total net product sales $73.5M (FILSPARI $49.6M); FY total $226.7M (FILSPARI $132.2M).","Plans to submit sNDA for FILSPARI in FSGS around end of Q1 2025, based on Phase 3 DUPLEX and Phase 2 DUET.","FDA granted full approval for IgAN in Sept 2024; received 693 new patient start forms in Q4.","Pegtibatinase Phase 3 HARMONY restart expected in 2026 after manufacturing scale-up improvements.","Cash and marketable securities $370.7M as of Dec 31, 2024, including $134.7M from Nov stock offering."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":233175000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172779,"accession_number":"0001438533-25-000004","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Travere plans sNDA for FILSPARI in FSGS after FDA Type C meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Completed Type C meeting with FDA; sNDA seeking traditional approval for FILSPARI in FSGS expected by end of Q1 2025.","sNDA will rely on existing Phase 3 DUPLEX and Phase 2 DUET study data for FILSPARI.","PARASOL workgroup findings show proteinuria reduction over 24 months strongly linked to lower kidney failure risk in FSGS.","If approved, FILSPARI could become first and only approved therapy indicated for FSGS, a rare kidney disorder."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172778,"accession_number":"0001438533-25-000002","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere reports ~$74M preliminary Q4 net product sales; FILSPARI PSFs up 40% QoQ","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 FILSPARI net sales ~$50M; total Q4 net product sales ~$74M; FY2024 ~$227M.","Received 693 new FILSPARI patient start forms in Q4, a 40% sequential increase in net sales vs Q3.","Cash, equivalents and marketable securities ~$371M at year-end 2024.","FDA accepted sNDA to modify liver monitoring for FILSPARI in IgAN; PDUFA date Aug 28, 2025.","On track for FSGS regulatory pathway update by Q4 2024 earnings call; partner CSL Vifor milestone $17.5M upon European full approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":233175000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189796,"accession_number":"0001193125-24-254153","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Travere Therapeutics prices $125M public offering of 7.8M shares at $16.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 7,812,500 shares at $16.00 per share; gross proceeds of $125.0M.","Net proceeds expected ~$117.0M after underwriting discounts and expenses.","Underwriters have 30-day option to purchase up to 1,171,875 additional shares.","Closing expected November 12, 2024; Jefferies and Leerink Partners are joint book-runners.","Proceeds for general corporate purposes including commercialization and R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189795,"accession_number":"0001438533-24-000046","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere reports Q3 net loss $54.8M; FILSPARI sales $35.6M, full FDA approval in IgAN","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $61.0M (FILSPARI $35.6M); 505 new PSFs in Q3; 2,989 total since launch.","Full FDA approval for FILSPARI in IgAN on Sept 5, 2024; broader label and orphan exclusivity to 2031.","R&D $51.7M, SG&A $65.6M; net loss $54.8M ($0.70/share); cash $277.4M.","sNDA submitted to modify liver monitoring; Type C meeting with FDA scheduled for FSGS path.","Voluntary halt of enrollment in Phase 3 HARMONY (pegtibatinase) due to manufacturing scale-up; restart expected 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":158388000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206307,"accession_number":"0001438533-24-000038","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Travere pauses Phase 3 HCU trial enrollment due to manufacturing scale-up issues; restart expected in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntary pause of enrollment in Phase 3 HARMONY Study for pegtibatinase (classical homocystinuria).","Desired drug substance profile not achieved in recent scale-up process; process improvements needed.","Currently enrolled patients continue to receive study medication from small scale batches without disruption.","Earliest date to restart enrollment expected in 2026 while company evaluates commercial process improvements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206306,"accession_number":"0001438533-24-000035","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants full approval to Travere's FILSPARI for IgA nephropathy based on PROTECT study","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA full approval for FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN at risk of disease progression.","PROTECT Study: FILSPARI showed mean eGFR slope -3.0 vs -4.2 mL/min/1.73 m2/year for irbesartan (p=0.0168), a 1.2 mL/min/year treatment effect.","FILSPARI reduced proteinuria by 49.8% vs 15.1% at Week 36 (p<0.0001); effect durable to two years.","Company plans to submit sNDA for potential modification to liver-monitoring REMS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206305,"accession_number":"0001438533-24-000030","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere Q2 FILSPARI sales $27.1M, up 37% Q/Q; 521 new patient start forms","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $52.2M (incl. $27.1M FILSPARI); total revenue $54.1M.","Net loss $70.4M ($0.91/share); adjusted net loss $50.1M ($0.65/share).","Cash & equivalents $325.4M at June 30, 2024.","PDUFA target date Sept 5, 2024 for FILSPARI full approval in IgAN.","Received 521 PSFs in Q2; 2,484 total since launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":95490000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223401,"accession_number":"0001438533-24-000022","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 2.7M share increase under 2018 Equity Plan, re-elect all directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All ten director nominees elected; John A. Orwin received 43.7M for vs 14.9M withheld.","2018 Equity Plan amended to add 2.7M authorized shares; vote 36.4M for, 22.1M against.","Advisory say-on-pay passed with 55.8M for, 2.9M against, 42k abstain.","Ernst & Young ratified as FY2024 auditor with 60.5M for, 2.2M against, 52k abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223400,"accession_number":"0001438533-24-000019","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere Q1: FILSPARI sales $19.8M; FDA Priority Review for full approval by Sept 5","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $40.0M (Q1 2024), up from $24.2M YoY, driven by FILSPARI launch.","FILSPARI net sales $19.8M; 511 new PSFs in Q1, total 1,963 since launch.","FDA granted Priority Review for sNDA to convert accelerated approval to full approval for IgAN; PDUFA Sept 5, 2024.","Net loss $136.1M ($1.76/share) vs $86.3M loss in Q1 2023, including $65M IPR&D milestone for pegtibatinase.","Cash, equivalents, and securities $441.0M as of March 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":41374000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223399,"accession_number":"0001438533-24-000016","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EU grants conditional marketing authorization for Travere's FILSPARI in IgA nephropathy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["European Commission approved FILSPARI (sparsentan) for adults with primary IgAN with urine protein excretion ≥1.0 g/day or UPCR ≥0.75 g/g.","Approval covers all EU member states plus Iceland, Liechtenstein, Norway; follows CHMP positive opinion in February 2024.","Decision based on pivotal Phase 3 PROTECT Study results; FILSPARI already has accelerated approval in the US.","CSL Vifor holds exclusive commercialization rights in Europe, Australia, New Zealand; expects launch in first European markets in H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242851,"accession_number":"0001438533-24-000007","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Travere and CSL Vifor receive CHMP positive opinion for sparsentan in IgAN in EU","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA CHMP recommended conditional marketing authorization for sparsentan for primary IgAN with proteinuria >1.0 g/day.","Positive opinion based on Phase 3 PROTECT Study results; EC final decision pending.","If approved, sparsentan would get CMA in all EU member states plus Iceland, Liechtenstein, Norway.","Already marketed in US as FILSPARI under accelerated approval for proteinuria reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242850,"accession_number":"0001438533-24-000003","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere Q4 net product sales $39.9M, FILSPARI PSFs total 1,452 in 2023; sNDA filing imminent","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of $39.9M in Q4 2023 ($127.5M FY); driven by FILSPARI launch ($14.7M Q4).","Q4 2023 net loss $90.2M ($1.18/sh); cash and equivalents $566.9M at Dec 31, 2023.","Received 459 new patient start forms for FILSPARI in Q4; total 1,452 PSFs since Feb 2023 approval.","Expects to submit sNDA for full U.S. approval of FILSPARI in IgAN in Q1 2024; CHMP opinion on EU CMA also Q1.","Pivotal Phase 3 HARMONY study of pegtibatinase in HCU enrolling; topline data expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":145238000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242849,"accession_number":"0001193125-24-003866","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere reports preliminary Q4 2023 net product sales ~$40M, FILSPARI sales $15M; cash $567M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2023 net product sales from continuing ops ~$40M; FY 2023 ~$128M.","FILSPARI net sales Q4 ~$15M (launch-to-date ~$30M); 459 new patient start forms in Q4.","Cash, cash equivalents & marketable securities ~$567M; expected to fund operations into 2028.","sNDA for full FILSPARI approval in IgAN on track for Q1 2024; CHMP opinion also expected Q1 2024.","Pivotal Phase 3 HARMONY study for pegtibatinase in HCU initiated; topline results expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":145238000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260222,"accession_number":"0001438533-23-000050","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"Travere announces successful pre-NDA for FILSPARI in IgAN, FSGS setback, and 20% workforce reduction","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Successful pre-NDA meeting for FILSPARI in IgA nephropathy; sNDA submission for full approval planned for Q1 2024.","Two-year Phase 3 DUPLEX results insufficient for FSGS sNDA; additional analyses planned with FDA re-engagement in 2024.","Company approves ~20% workforce reduction (non-field employees) as part of strategic reorganization; charges estimated $12-14M.","Majority of restructuring charges expected in Q4 2023; cash payments substantially complete by Q1 2024.","Focus on FILSPARI launch and pegtibatinase Phase 3 program for HCU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260221,"accession_number":"0001438533-23-000046","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere Q3 net income $150.7M from bile acid sale; FILSPARI sales $8M, 430 new starts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $150.7M ($1.97/share) includes gain from bile acid portfolio sale; prior year loss $69.7M.","FILSPARI net sales $8.0M in Q3, 430 new patient start forms (990 total since Feb 2023 launch).","R&D expense $60.6M, SG&A $67.8M; cash, equivalents & marketable securities $634.6M.","Regulatory: on track for sNDA for FILSPARI in IgAN (full approval) & FSGS in Q4; EU CHMP opinion year-end.","Completed sale of bile acid products to Mirum for up to $445M; pegtibatinase pivotal study to start by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":100179000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277511,"accession_number":"0001193125-23-239098","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Travere's FILSPARI misses eGFR total slope endpoint but achieves chronic slope significance in IgAN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["eGFR total slope difference vs irbesartan 1.0 mL/min/1.73m2 per year, p=0.058 (missed statistical significance).","eGFR chronic slope difference 1.1 mL/min/1.73m2 per year, p=0.037 (statistically significant).","Company to submit sNDA for full FDA approval of FILSPARI in IgAN in first half of 2024.","EU CMA decision for sparsentan in IgAN expected from CHMP around end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277507,"accession_number":"0001438533-23-000041","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K/A","filed_at":"2023-09-07T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Travere completes asset sale to Mirum for up to $445M; pro forma shows reduced continuing ops revenue","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Net cash proceeds of $210M at close plus up to $235M in milestones from sale of Chenodal/Cholbam to Mirum; estimated gain of $235M.","Pro forma continuing ops revenue for H1 2023: $63M (down from $116.7M), net loss $198.6M, EPS ($2.75).","Pro forma continuing ops revenue for FY2022: $109.5M (down from $212M), net loss $329.8M, EPS ($5.17).","Pro forma balance sheet at June 30, 2023: cash $277M, total assets $897M, equity $348M.","Milestone payments of up to $235M tied to annual net sales thresholds of $125M-$500M for divested products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277510,"accession_number":"0001193125-23-228130","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Travere closes $210M asset sale to Mirum; eligible for up to $235M in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash payment of $210M from Mirum for Chenodal and Cholbam assets.","Potential milestone payments up to $235M based on annual net sales tiers ($125M-$500M).","Transaction closed on August 31, 2023, as previously announced on July 16, 2023.","Pro forma financial statements to be filed by amendment within four business days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277509,"accession_number":"0001438533-23-000036","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere reports Q2 loss, FILSPARI launch progress, and $445M bile acid portfolio sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $85.6M ($1.13/share) vs $67M loss in prior year; revenue $59.7M from product sales $57M and licensing.","FILSPARI launch: 417 new patient start forms in Q2; net sales $3.5M in Q2, $6.5M since Feb approval.","Positive pegtibatinase Cohort 6 results: 67.1% mean tHcy reduction; Phase 3 study expected by year-end.","Agreement to sell bile acid portfolio (Cholbam, Chenodal) to Mirum for up to $445M ($210M upfront); close Q3 2023.","Cash $491.3M; topline confirmatory PROTECT data for IgAN sNDA expected late Q3/early Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":116690000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277508,"accession_number":"0001193125-23-187704","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Travere sells Chenodal and Cholbam assets to Mirum for up to $445M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to $445M: $210M at closing plus up to $235M in milestone payments tied to net sales.","Milestones triggered when annual net sales reach $125M-$500M; closing expected Q3 2023.","Assets include development, manufacturing, and commercialization rights for Chenodal and Cholbam (Kolbam).","Mirum to use specified efforts to achieve regulatory approval and milestones; termination date Oct 16, 2023, extended to Apr 16, 2024 for regulatory conditions.","Deal subject to HSR clearance, other consents; Travere provides transition services post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295455,"accession_number":"0001438533-23-000030","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Travere reports positive Phase 1/2 COMPOSE Cohort 6 data for pegtibatinase in HCU","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pegtibatinase 2.5 mg/kg twice weekly reduced total homocysteine (tHcy) by mean 67.1% vs placebo increase of 0.6%.","All 4 treated patients achieved mean tHcy below 100 µM threshold; one patient with low baseline achieved normalization.","No treatment-related serious adverse events, anaphylaxis, or discontinuations in cohort 6.","Methionine reduced and cystathionine elevated, consistent with desired CBS enzyme activity.","Company plans to initiate Phase 3 program by end of 2023 after regulatory engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295454,"accession_number":"0001438533-23-000027","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Travere stockholders approve 2.7M share increase to 2018 equity incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment increasing authorized shares under 2018 Equity Incentive Plan by 2,700,000 shares.","Ten directors elected; John Orwin received 50.65M for vs 10.99M withheld.","Advisory vote on named executive officer compensation passed with 56.25M for, 5.36M against.","Ernst & Young ratified as independent auditor for FY2023 with 63.81M for, 30K against.","Plan document filed as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295453,"accession_number":"0001438533-23-000023","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere Q1 net loss $86.3M; FILSPARI launch nets $3M in 6 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $50.3M (incl. $3M FILSPARI), up from $46.4M YoY; net loss $86.3M ($1.27/share) vs $76M ($1.20).","Cash $561.5M after $216M stock offering and $23M milestone to Ligand for FILSPARI approval.","FILSPARI launched week of Feb 27; 146 new patient start forms received in first 6 weeks.","Phase 3 DUPLEX in FSGS missed primary eGFR slope endpoint; company to engage regulators on path forward.","EMA decision on sparsentan for IgAN expected H2 2023; PROTECT confirmatory data due Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":56993000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295452,"accession_number":"0001438533-23-000018","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Travere's sparsentan misses primary eGFR endpoint in Phase 3 FSGS study; proteinuria trends favorable","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["eGFR total slope difference 0.3 mL/min/1.73m2/yr favoring sparsentan (p=0.7491), not statistically significant.","eGFR chronic slope difference 0.9 mL/min/1.73m2/yr (p=0.4203), also not significant.","Proteinuria reduced 50% with sparsentan vs 32% with irbesartan at week 108; FPRE 38% vs 23%.","Company plans to engage FDA and EMA to explore potential path for regulatory submission.","Sparsentan well-tolerated with safety profile comparable to irbesartan through 108 weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295451,"accession_number":"0001438533-23-000012","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-04-12T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Travere Therapeutics dismisses BDO as auditor, appoints EY; discloses material weakness in internal controls","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BDO dismissed as independent auditor effective April 6, 2023; EY appointed for fiscal year ending Dec 31, 2023.","BDO's audit reports for FY2022 and FY2021 were unqualified with no adverse opinion or modifications.","Disclosed material weakness in controls over pre-launch inventory contract affecting R&D expense timing; no restatement required.","No disagreements with BDO on accounting principles or audit scope during 2022, 2021, or interim period through April 6, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316008,"accession_number":"0001193125-23-056553","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Travere Therapeutics prices $200M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 8,275,000 shares at $21.00/share and 1,250,000 pre-funded warrants at $20.9999 each.","Gross proceeds ~$200M; net proceeds ~$187.6M after underwriting discounts and expenses.","Proceeds to support commercial launch of FILSPARI (sparsentan) for IgAN and potential FSGS launch.","Underwriters granted 30-day option to purchase up to 1,428,750 additional shares.","Closing expected March 3, 2023; Jefferies, J.P. Morgan, BofA Securities, SVB Securities as joint book-runners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316007,"accession_number":"0001438533-23-000006","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere reports Q4 2022 net loss $65.8M; FDA granted accelerated approval for FILSPARI in IgAN","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $52.3M in Q4 2022 vs $54.6M in Q4 2021; full year $200.5M vs $210.8M.","Net loss $65.8M ($1.03 per share) in Q4 2022 vs $51.6M ($0.84) in Q4 2021; full year loss $278.5M.","Cash and marketable securities $450.2M as of Dec 31, 2022.","FDA granted accelerated approval of FILSPARI (sparsentan) for IgAN on Feb 17, 2023; commercial launch expected week of Feb 27.","Topline data from DUPLEX Study (FSGS) expected Q2 2023; EMA decision on sparsentan for IgAN expected H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":212018000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316006,"accession_number":"0001438533-23-000002","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-02-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants accelerated approval to Travere's FILSPARI for IgA nephropathy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved FILSPARI (sparsentan) to reduce proteinuria in adults with primary IgA nephropathy at risk of rapid progression; continued approval contingent on confirmatory data.","FILSPARI showed 45% mean reduction in proteinuria vs 15% for irbesartan in post-hoc sensitivity analysis (label data).","Travere expects to pay $23M milestone to Ligand and BMS in Q1 2023 due to approval.","Topline confirmatory endpoint results from PROTECT Study expected Q4 2023; DUPLEX FSGS results expected Q2 2023.","FILSPARI to be available week of Feb 27, 2023; estimated addressable US patients 30,000-50,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316005,"accession_number":"0001193125-23-004120","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere reports preliminary Q4 rev ~$52M; sparsentan PDUFA Feb 17, 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary net product sales Q4 2022 ~$52M; full year 2022 net product sales ~$201M, total revenue $212M.","Ended 2022 with ~$450M in cash, cash equivalents, and marketable securities.","FDA PDUFA for sparsentan in IgAN set for Feb 17, 2023; potential Q1 2023 launch if approved.","Phase 3 PROTECT (IgAN) topline confirmatory results expected Q4 2023; DUPLEX (FSGS) topline Q2 2023.","Phase 3 trial for pegtibatinase (HCU) to begin H2 2023; RESTORE study for CTX completion expected in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":212018000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334307,"accession_number":"0001438533-22-000049","cik":1438533,"company_name":"Travere Therapeutics, Inc.","ticker":"TVTX","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Travere Q3 net loss $69.7M; PDUFA for sparsentan extended to Feb 17, 2023; EMA accepts CMA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $69.7M ($1.09/share) vs $35.6M ($0.59) YoY; adjusted net loss $48.9M ($0.76).","Net product sales $50.8M, down from $54.2M; total revenue $53.5M.","FDA set new PDUFA date Feb 17, 2023 for sparsentan in IgAN after REMS update.","EMA accepted CMA application for sparsentan in IgAN; decision expected H2 2023.","Cash, equivalents & marketable securities $506.3M; DUPLEX FSGS data expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":156150000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4392054733.25649,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-10-27T23:59:59+00:00|334307"}